|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that various carcinogenic factors may cause distinct TERT promoter mutations in BCC and that TERT promoter mutations might be associated with a poorer prognosis in melanoma.
|
24691053 |
2014 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Overall, TERT promoter alterations were among the most prevalent aberrations in this population, with very high rates in brain cancers (48% of patients) and melanomas (56% of patients).
|
29211306 |
2018 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Paradoxically, we observed shorter telomeres (P = 1 × 10<sup>-5</sup> ) in primary tumors from unrelated melanoma patients with (121) than without (170) somatic TERT promoter mutations that similar to the germline mutation, also create binding motifs for ETS transcription factors.
|
30203894 |
2018 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Previously, the TERT promoter mutations were shown to associate with markers of poor outcome and reduced survival in patients with primary melanoma.
|
30070694 |
2019 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recently, frequent somatic mutations in the TERT promoter have been described in several tumor entities such as melanoma, glioblastoma, bladder cancer, and hepatocellular carcinoma.
|
25267585 |
2014 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recurrent somatic mutations in the TERT promoter region were first reported in human melanomas.
|
25862495 |
2015 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to test the hypothesis that MUP and mucosal melanomas harbor different prevalences of TERT-promoter mutations.
|
24463461 |
2014 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aims of this study were to assess the prognostic potential of solar elastosis grading and telomerase reverse transcriptase (TERT) promoter mutations (TERTp) in melanoma and to evaluate whether an association between solar elastosis and TERTp exists.
|
29570169 |
2018 |
|
LOC110806263
|
0.100 |
Biomarker
|
disease |
BEFREE |
The etiology and pathogenesis of the pediatric melanoma is currently being investigated; studies have examined the genetic alterations that may be involved with the development of pediatric melanomas including TERT promoter, BRAF, and NRAS among others.
|
29485257 |
2018 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The frequency of TERT promoter germline mutations in families with melanoma in our population is extremely rare.
|
30451293 |
2019 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The rarity of TERT promoter mutation in the acral lentiginous melanoma was consistent with the supposed role of UV light in the melanoma pathogenesis and also corroborated the view that acral lentiginous melanomas have a different pathogenesis with the melanomas from sun-exposed sites.
|
24588324 |
2014 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The role of TERT promoter mutations in differentiating recurrent nevi from recurrent melanomas: A retrospective, case-control study.
|
30287318 |
2019 |
|
LOC110806263
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results indicate that AdRGD combined with transcriptional regulation using Tyr or TERT promoter is a potentially useful and safe vector system for suicide gene therapy for melanoma.
|
15746944 |
2005 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To determine the prognostic value of TERT alterations in AYA melanoma, we investigated the association of TERT promoter mutations, as well as promoter methylation, an epigenetic alteration also linked to TERT upregulation, with TERT mRNA expression and outcome using a well-characterized cohort of 27 patients with melanoma (ages 8-25, mean 20).
|
28378855 |
2017 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We found that the activating TERT promoter mutations reported in melanoma are also frequent in squamous cell carcinoma (50%) and basal cell carcinoma, the latter including both sporadic tumors (78%) and tumors from patients with nevoid basal cell carcinoma syndrome (68%).
|
24030752 |
2014 |
|
LOC110806263
|
0.100 |
Biomarker
|
disease |
BEFREE |
We then screened the TERT promoter in sporadic melanoma and observed recurrent ultraviolet signature somatic mutations in 125 of 168 (74%) of human cell lines derived from metastatic melanomas, 45 of 53 corresponding metastatic tumor tissues (85%), and 25 of 77 (33%) primary melanomas.
|
23348503 |
2013 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We validated μ-cisTarget by re-analyzing the TAL1 and LMO1 enhancer mutations in T-ALL, and the TERT promoter mutation in melanoma.
|
28854983 |
2017 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
With the recent discovery of recurrent mutations in the TERT promoter in melanoma, identification of other somatic causal promoter mutations is of considerable interest.
|
26082173 |
2015 |